Johnson & Johnson runs two distinct businesses under one roof. The first, called Innovative Medicine, makes prescription drugs for cancer, immune diseases, mental health conditions, and more. The second, called MedTech, makes the physical tools doctors use — heart catheters, contact lenses, surgical staplers, and joint implants. Every time a doctor writes a prescription for DARZALEX or a surgeon uses a Shockwave device to clear a blocked artery, Johnson & Johnson collects revenue. The company earns money each time one of its products is used or prescribed, across roughly every country on earth. The diagram below traces where the money goes.
How Johnson & Johnson Makes Money
flowchart TD
A["R&D Creates New Drugs and Devices"] -->|"patents filed on products"| B["Patents Protect Pricing Power"]
B --> C["Innovative Medicine\nDAZARLEX top product $14.4B"]
B --> D["MedTech Devices\nElectrophysiology $5.6B"]
C -->|"sold to hospitals and wholesalers"| E["Total Revenue $94.2B"]
D -->|"sold to hospitals and surgeons"| E
E --> F["Free Cash Flow $19.7B"]
F -->|"funds next R&D cycle"| A
Five years of financial data tell a story with a sharp dip in the middle and a recovery that has now exceeded where the company started. Revenue fell from $93.8 billion in 2022 to $85.2 billion in 2023 — a drop driven largely by biosimilar versions of STELARA entering the market and taking sales away from the original. Biosimilar drugs are cheaper copies of complex medicines; when they launch, original drug sales can fall fast. Revenue then climbed back to $88.8 billion in 2024 and reached $94.2 billion in 2025, surpassing the 2022 level.
What is a biosimilar?
A biosimilar is a near-identical copy of a complex biological drug, made by a different company after the original's patent expires. When biosimilars launch, they typically cost less, so hospitals and insurers switch patients over. This can wipe out a large chunk of the original drug's sales very quickly.
Annual Revenue ($ billions)
Revenue dipped sharply in 2023 as STELARA biosimilars launched globally, then recovered as oncology drugs — especially DARZALEX — picked up the slack.
What drove the recovery? Mainly the Oncology portfolio. DARZALEX, a treatment for multiple myeloma — a blood cancer — grew from $11.7 billion in 2024 to $14.4 billion in 2025, a 23% jump. ERLEADA for prostate cancer, CARVYKTI for blood cancer, and newer drugs like SPRAVATO for hard-to-treat depression all grew fast. Oncology as a whole hit $25.4 billion in 2025. Meanwhile, the MedTech side grew 6.1% to $33.8 billion, helped by strong Cardiovascular results including the Shockwave device for calcified arteries and the Abiomed heart pump.
$14.7B
Spent on research and development in 2025 — about 15.6% of total revenue — funding the next wave of drugs and devices
The cash engine has stayed remarkably steady even as revenue moved around. Operating cash flow was $23.4 billion in 2022, dipped slightly to $22.8 billion in 2023, and climbed to $24.5 billion in 2025. Free cash flow — the money left after building and maintaining factories — held near $19–20 billion every year. The company paid $12.4 billion in dividends and spent $6.0 billion buying back its own stock in 2025 alone. One notable shift: net debt rose sharply from $7.5 billion in 2023 to $28.2 billion in 2025, largely because the company borrowed $9.2 billion in early 2025 to acquire Intra-Cellular Therapies and its drug CAPLYTA for approximately $14.5 billion.
$24.5B
Operating cash flow in 2025 — the highest in the five-year period shown, despite a heavier debt load
The risks are specific and documented. The biggest involves DARZALEX itself. It accounts for roughly 15% of total company revenue, and the two key patents that protect it expire in the United States in 2029. The royalty payments alone to Genmab — the company that originally developed the core antibody — were $2.4 billion in 2025. When the patent clock runs out and biosimilars arrive, the revenue drop could be severe unless newer drugs fill the gap in time.
2025
milestone
Orthopaedics separation announced
In October 2025, Johnson & Johnson announced plans to split off its Orthopaedics business — which includes hip replacements, knee implants, spine products, and trauma devices — into a separate company. The targeted timeline is 18 to 24 months. Orthopaedics generated $9.3 billion in revenue in 2025. This move would make the remaining company more concentrated in higher-growth areas like Oncology and Cardiovascular devices.
A second risk comes from the U.S. government. Under the Inflation Reduction Act, Washington can now set prices for certain high-spending drugs covered by Medicare, the government health program for older Americans. Starting in 2026, drugs including XARELTO and previously STELARA faced government-set price ceilings. ERLEADA was added to the 2028 selected drug list. If the government sets prices well below what the company currently charges, the profit margin on those drugs shrinks. Johnson & Johnson has filed a legal challenge, but the outcome is uncertain.
How the Inflation Reduction Act affects drug prices
The U.S. Inflation Reduction Act lets the government negotiate — or effectively set — prices for certain drugs that Medicare spends the most on. Drug companies must accept the government's price or face steep taxes. The program started for some drugs in 2026 and expands over time. It does not affect what private insurers pay, only the Medicare population.
Then there are the talc lawsuits. For years, people have sued Johnson & Johnson claiming that talc-based body powder — including the well-known Johnson's Baby Powder — caused cancer. The company set aside large reserves for these claims. In 2024, the company booked $5.1 billion in charges related to talc. In 2025, it reversed approximately $7.0 billion of that reserve — a sign it expects to resolve the claims for less than previously feared — but roughly $3.4 billion remains set aside and the litigation is not finished. A worse-than-expected outcome could still cost the company significantly.
$3.4B
Reserve still held for talc-related legal claims as of the end of 2025 — the final cost remains unresolved
There are also supply chain and geopolitical pressures. The company runs 63 manufacturing facilities and depends on thousands of suppliers worldwide. Tariffs, trade tensions between the U.S. and China, and currency swings all affect costs — particularly in MedTech, where the company noted tariffs and unfavorable currency as specific drags in 2025. China's volume-based procurement program, which forces hospitals to buy the cheapest available product, has already cut into Surgery and Orthopaedics sales there.
New products introduced in the past five years accounted for roughly 25% of 2025 sales — a sign that the pipeline is already contributing meaningfully, not just promising future returns.
The Bet
DARZALEX accounts for roughly 15% of total revenue and its core U.S. patents expire in 2029. The next generation of cancer drugs — CARVYKTI, RYBREVANT, TECVAYLI, TALVEY, and others still in clinical trials — has to grow large enough, fast enough, to replace what DARZALEX will likely lose to biosimilars before the decade is out. If those newer drugs reach sufficient scale and the pipeline delivers additional approvals on schedule, the Oncology engine keeps running. If the pipeline stumbles or biosimilar erosion on DARZALEX arrives faster than expected, the revenue base that funds all of the company's research spending starts to shrink at its foundation.
Open question
Johnson & Johnson is actively reshaping itself — spinning off Orthopaedics, absorbing the Intra-Cellular acquisition, fighting the Inflation Reduction Act in court, and racing to build new cancer drugs before DARZALEX patents expire in 2029. The cash flows are large and consistent. But the company is taking on more debt, facing government price controls, and managing a legal overhang on talc that is not yet fully resolved. Can the oncology pipeline grow fast enough — and the new acquisitions prove their worth quickly enough — to keep revenue rising after DARZALEX meets its patent cliff, all while the government gains more power to set the prices of the drugs that matter most?
Compiled · 10-K · FY2025
Regulatory Pricing Controls
The U.S. government's Inflation Reduction Act starting in 2026 will let the government set prices for certain of the company's medicines instead of the company choosing prices itself. This could significantly reduce profits from these drugs, and the company faces potential penalties if it doesn't follow the government's rules about this new pricing system.
Manufacturing and Supply Chain Disruption
The company operates 63 manufacturing facilities and relies on thousands of suppliers worldwide. Any disruption—like natural disasters, quality problems, labor shortages, or supplier failures—could cause product shortages and lost sales. Finding replacement suppliers takes time and costs money, which could hurt the business badly.
Patent Challenges
Competitors regularly challenge the company's patents in court to make generic or copied versions of popular drugs before the original patent expires. If the company loses these legal battles, it can lose a huge portion of a drug's sales in a very short time.
Product Liability and Talc Lawsuits
The company faces many lawsuits from people claiming injuries from body powders containing talc, particularly Johnson's Baby Powder. The company could be ordered to pay large sums of money in settlements or court judgments, which could materially affect profits and cash flow.
Geopolitical and Trade Risks
The Russia-Ukraine war, Middle East conflict, and U.S.-China tensions are disrupting the company's global supply chain and increasing costs. The U.S. government may impose tariffs on products made overseas, and other countries may retaliate with their own tariffs, making it more expensive for the company to do business worldwide.
10-K Item 1A · Risk Factors
